Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Albanell

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Tumori|November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)A Ribas, J Bellmunt, J Albanell, et al.
Cancer Research|August 28, 2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatmentsJ Albanell, J Codony-Servat, F Rojo, et al.
Endocrine-Related Cancer|May 27, 2006
Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patientsC Montagut, I Tusquets, B Ferrer, et al.
British Journal of Cancer|November 10, 2005
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapseJ Domingo-Domenech, B Mellado, B Ferrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2011
Circulating cancer cells in division in an early breast cancer patientM J Serrano, R Nadal, J A Lorente, et al.
Oncoimmunology|January 9, 2018
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumabM Hardy-Werbin, O Arpí, A Taus, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa studyM Martin, P Fumoleau, J A Dewar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Tumori|November 1, 1996
Early results of the value of p53 in predicting survival in a homogeneous cohort of patients with invasive bladder cancer treated with a neoadjuvant carboplatin-based regimen (M-CAVI)A Ribas, J Bellmunt, J Albanell, et al.
Cancer Research|August 28, 2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatmentsJ Albanell, J Codony-Servat, F Rojo, et al.
Endocrine-Related Cancer|May 27, 2006
Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patientsC Montagut, I Tusquets, B Ferrer, et al.
British Journal of Cancer|November 10, 2005
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapseJ Domingo-Domenech, B Mellado, B Ferrer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2011
Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activityJ Bellmunt, J L González-Larriba, C Prior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2011
Circulating cancer cells in division in an early breast cancer patientM J Serrano, R Nadal, J A Lorente, et al.
Oncoimmunology|January 9, 2018
Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumabM Hardy-Werbin, O Arpí, A Taus, et al.
American Journal of Clinical Oncology|August 1, 1996
M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladderJ Bellmunt, A Ribas, J Albanell, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2016
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa studyM Martin, P Fumoleau, J A Dewar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 11, 2009
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxelC Sessa, D Tosi, L Viganò, et al.
Pageof 10